Search

Displaying results 281 - 290 of 1777 in total
  1. Drug

    Eftrenonacog alfa

    go.drugbank.com/drugs/DB11608
    Approved

    It was first approved by the FDA in March 2014 and later approved by the EMA in May 2016. … factor IX (FIX), leading to decreased levels of endogenous factor IX and increased susceptibility to recurrent bleeding episodes caused spontaneously or as a result of accidental or surgical trauma [FDA

  2. Drug

    Gadofosveset trisodium

    go.drugbank.com/drugs/DB06705
    Approved

    Gadofosveset trisodium is an intravenous contrast agent used with magnetic resonance angiography(MRA), which is a non-invasive way of imaging blood vessels. … The agent allows for the vascular system to be imaged more clearly by the MRA. In this way, gadofosveset trisodium is used to help diagnose certain disorders of the heart and blood vessels.

  3. Drug

    Venetoclax

    go.drugbank.com/drugs/DB11581
    ApprovedInvestigational

    Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 [FDA label]. … Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small lymphocytic lymphoma [FDA label]. CLL is the most prevalent leukemia diagnosed in Western countries [A40022].

  4. Drug

    Cholecalciferol

    go.drugbank.com/drugs/DB00169
    ApprovedInvestigationalNutraceutical

    Vitamin D, in general, is a secosteroid generated in the skin when 7-dehydrocholesterol located there interacts with ultraviolet irradiation - like that commonly found in sunlight . Both the endogenous form of vitamin D (that results fro...

    Mixtures: Prenatabs FA, PNV 27-Ca/Fe/FA
  5. Drug

    Rituximab

    go.drugbank.com/drugs/DB00073
    ApprovedInvestigational

    FDA in 1997 as a single agent to treat patients with B-cell Non-Hodgkin's Lymphoma (NHL) [L4811], however, has now been approved for a variety of conditions [FDA label]. … On November 28, 2018, the US FDA approved _Truxima_, the first biosimilar to Rituxan (Rituximab) [L4808].

  6. Drug

    Terazosin

    go.drugbank.com/drugs/DB01162
    ApprovedInvestigational

    Terazosin is a quinazoline derivative alpha-1-selective adrenergic blocking agent indicated for benign prostatic hyperplasia and hypertension[FDA Label][A176831].

  7. Drug

    Torasemide

    go.drugbank.com/drugs/DB00214
    ApprovedInvestigational

    [A319] Torasemide was first approved for clinical use by the FDA in 1993.[L5257]

  8. Drug

    Enasidenib

    go.drugbank.com/drugs/DB13874
    ApprovedInvestigational

    Enasidenib is an orally available treatment for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with specific mutations in the isocitrate dehydrogenase 2 (IDH2) gene, which is a recurrent mutation...

  9. Drug

    Scorpion (centruroides) immune Fab2 antivenin (equine)

    go.drugbank.com/drugs/DB13905
    Approved

    It was approved by FDA in 2011 and is marketed under the name Anascorp [L2196]. Anascorp is produced from equine IgG antibodies.

  10. Drug

    Ephedrine

    go.drugbank.com/drugs/DB01364
    ApprovedInvestigational

    [A193701,A193704,L12975] Ephedrine was granted a type 7 FDA Approval on 29 April 2016.[L12975]

    Mixtures: FLUKOL X-TRA, PIM-TRA-KOL RASA LEMON